Erratum: Evaluation and management of hyponatremia: An emerging role for vasopressin receptor antagonists (Nature Clinical Practice Nephrology (2007) 3, (82-95) DOI: 10.1038/ncpneph0401);Evaluation and management of hyponatremia: An emerging role for vasopressin receptor antagonists

Nature Clinical Practice Nephrology

Volumn 3, Issue 2, 2007, Pages 82-95

  Chen, Sheldon ^a   Jalandhara, Nishant ^b   Batlle, Daniel ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aquaretics; Electrolyte free water clearance; Hyponatremia; Vasopressin antagonists

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CONIVAPTAN; DEMECLOCYCLINE; DIURETIC AGENT; FUROSEMIDE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; LIXIVAPTAN; MEVINOLIN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PLACEBO; RITONAVIR; ROSUVASTATIN; RWJ 351647; SIMVASTATIN; SODIUM CHLORIDE; TOLVAPTAN; UNCLASSIFIED DRUG; UREA; VASOPRESSIN RECEPTOR ANTAGONIST;

CALCULATION; CLEARANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE BALANCE; ELECTROLYTE EXCRETION; ELECTROLYTE URINE LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; MICTURITION; MYELIN DEFICIENCY; MYELINOLYSIS; NEPHROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSMOLARITY; PAIN; PATHOLOGY; PHLEBITIS; POLYURIA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVIEW; SIDE EFFECT; STEADY STATE; THIRST; UREMIA; VOLUMETRY; WATER ABSORPTION; XEROSTOMIA;

EID: 33846521902     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0450     Document Type: Erratum

References (68)

1. Robertson GL (2001) Antidiuretic hormone: normal and disordered function. Endocrinol Metab Clin North Am 30: 671-694
2. Costello-Boerrigter LC et al. (2003) Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am 87: 475-491
3. Hayashi M et al. (1994) Expression and distribution of aquaporin of collecting duct are regulated by vasopressin V2 receptor in rat kidney. J Clin Invest 94: 1778-1783
4. Wong LL and Verbalis JG (2002) Systemic diseases associated with disorders of water homeostasis. Endocrinol Metab Clin North Am 31: 121-140
5. Decaux G et al. (2000) Hyponatremia in the intensive care: from diagnosis to treatment. Acta Clin Belg 55: 68-78
6. Brown OA (2004) Understanding postoperative hyponatremia. Urol Nurs 24: 197-201
7. Casulari LA et al. (2004) Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci 48: 11-18
8. Coenraad MJ et al. (2001) Hyponatremia in intracranial disorders. Neth J Med 58: 123-127
9. Janicic N and Verbalis JG (2003) Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 32: 459-481
10. Soupart A and Decaux G (1996) Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 46: 149-169
11. Gross P et al. (2001) Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 12 (Suppl): S10-S14
12. Sterns RH (1987) Severe symptomatic hyponatremia: treatment and outcome: a study of 64 cases. Ann Intern Med 107: 656-664
13. Fried LF and Palevsky PM (1997) Hyponatremia and hypernatremia. Med Clin North Am 81: 585-609
14. Boscoe A et al. (2006) Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc 4: 10-20
15. Greenberg A and Verbalis JG (2006) Vasopressin receptor antagonists. Kidney Int 69: 2124-2130
16. Baylis PH (2003) The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 35: 1495-1499
17. Palmer BF (2003) Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 14: 182-187
18. Mulloy AL and Caruana RJ (1995) Hyponatremic emergencies. Med Clin North Am 79: 155-168
19. Goh KP (2004) Management of hyponatremia. Am Fam Physician 69: 2387-2394
20. Adrogue HJ and Madias NE (2000) Hyponatremia. N Engl J Med 342: 1581-1589
21. Moritz ML and Ayus JC (2003) The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 18: 2486-2491
22. Fraser CL and Arieff AI (1997) Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 102: 67-77
23. Sterns RH et al. (1994) Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 4: 1522-1530
24. Ayus JC et al. (2006) Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents. Kidney Int 69: 1319-1325
25. Ghali JK et al. (2006) Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin-receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91: 2145-2152
26. Rabinstein AA and Wijdicks EF (2003) Hyponatremia in critically ill neurological patients. Neurologist 9: 290-300
27. Harrigan MR (2001) Cerebral salt wasting syndrome. Crit Care Clin 17: 125-138
28. Shoker AS (1994) Application of the clearance concept to hyponatremic and hypernatremic disorders: a phenomenological analysis. Clin Chem 40: 1220-1227
29. Ayus JC et al. (1987) Treatment of symptomatic hyponatremia and its relation to brain damage. N Engl J Med 317: 1190-1195
30. Rose BD (1986) New approach to disturbances in the plasma sodium concentration. Am J Med 81: 1033-1040
31. Edelman IS et al. (1958) Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 37: 1236-1256
32. Furst H et al. (2000) The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 319: 240-244
33. Schrier RW (1985) Treatment of hyponatremia. N Engl J Med 312: 1121-1123
34. Decaux G and Soupart A (2003) Treatment of symptomatic hyponatremia. Am J Med Sci 326: 25-30
35. Decaux G (2001) Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110: 582-584
36. Decaux G et al. (1980) Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 69: 99-106
37. Decaux G et al. (1981) Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med 304: 329-330
38. Forrest JN et al. (1978) Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 298: 173-177
39. Han DS and Cho BS (2002) Therapeutic approach to hyponatremia. Nephron 92: 9-13
40. Kleinschmidt-Demasters BK et al. (2006) Central and extrapontine myelinolysis: then...and now. J Neuropathol Exp Neurol 65: 1-11
41. Laureno R and Karp BI (1997) Myelinolysis after correction of hyponatremia. Ann Intern Med 126: 57-62
42. Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11: 406-410
43. Nielsen S et al. (1995) Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 92: 1013-1017
44. DiGiovanni SR et al. (1994) Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci USA 91: 8984-8988
45. Rai T (1997) Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol 8: 1357-1362
46. Saito T et al. (1997) Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. J Clin Endocrinol Metab 82: 1823-1827
47. Martin P-Y et al. (1999) Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 10: 2165-2170
48. Wong LL and Verbalis JG (2001) Vasopressin V2 receptor antagonists. Cardiovasc Res 51: 391-402
49. Verbalis JG (2002) Vasopressin V2 receptor antagonists. J Mol Endocrinol 29: 1-9
50. Schrier RW et al. (2001) Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis 3: 210-214
51. Goldsmith SR and Gheorghiade M (2005) Vasopressin antagonism in heart failure. J Am Coll Cardiol 46: 1785-1791
52. Gheorghiade M (2006) The clinical effects of vasopressin receptor antagonists in heart failure. Cleve Clin J Med 73 (Suppl 2): S24-S29
53. Saito T et al. (1997) Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82: 1054-1057
54. Gross P (2004) Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia. J Am Soc Nephrol 15: 353A
55. Udelson JE et al. (2001) Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417-2423
56. Verbalis JG et al. (2004) Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. J Am Soc Nephrol 15: 356A
57. Lemmens-Gruber R and Kamyar M (2006) Vasopressin antagonists. Cell Mol Life Sci 63: 1766-1779
58. Wong F et al. (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37: 182-191
59. Gerbes AL et al. (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double blind multicenter trial. Gastroenterology 124: 933-939
60. Abraham WT et al. (2006) Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47: 1615-1621
61. Decaux G (2001) Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPS 985. J Lab Clin Med 138: 18-21
62. Gheorghiade M et al. (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double blind, randomized trial. Circulation 107: 2690-2696
63. Gheorghiade M et al. (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV in CHF). JAMA 291: 1963-1971
64. 2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 97: 1064-1067
65. Costello-Boerrigter LC et al. (2006) Vasopressin-2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excetion in human heart failure. Am J Physiol Renal Physiol 290: F273-F278
66. Gheorghiade M et al. (2005) Rationale and design of the multicenter, randomized, double blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with Tolvaptan (EVEREST). J Card Fail 11: 260-269
67. 2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112
68. Gunnet J et al. (2006) Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. Clin Exp Pharmacol Physiol 33: 320-326